Table 4.
Androgen and progesterone metabolites of patients with breast cancer and normal controls
| Control | Breast cancer | P | OR (95% CI)* | P * | |
|---|---|---|---|---|---|
| Dehydroepiandrosterone | 70.827 ± 87.698 | 105.461 ± 149.062 | 0.346 | 1.004 (0.998-1.009) | 0.229 |
| Androstenedione | 9.625 ± 10.045 | 15.979 ± 16.009 | 0.116 | 1.04 (0.985-1.097) | 0.155 |
| Androsterone | 489.995 ± 258.941 | 629.159 ± 347.064 | 0.129 | 1.001 (0.999-1.003) | 0.203 |
| Etiocholanolone | 637.655 ± 315.028 | 607.3 ± 338.631 | 0.75 | 1 (0.998-1.001) | 0.637 |
| Testosterone | 0.888 ± 1.104 | 3.566 ± 4.719 | 0.014 | 1.491 (1.001-2.219) | 0.049 |
| 5α-Dihydrotestosterone | 0.519 ± 0.662 | 0.616 ± 0.571 | 0.586 | 1.244 (0.479-3.233) | 0.654 |
| 5α-Androstanediol | 6.531 ± 7.231 | 7.709 ± 4.319 | 0.482 | 1.021 (0.904-1.153) | 0.742 |
| 5β-Dihydrotestosterone | 0.41 ± 0.943 | 0.211 ± 0.343 | 0.309 | 0.58 (0.212-1.588) | 0.289 |
| 5β-Androstanediol | 7.004 ± 6.435 | 6.27 ± 4.115 | 0.629 | 0.968 (0.868-1.08) | 0.562 |
| Pregnanediol | 856.489 ± 1400.928 | 791.032 ± 716.645 | 0.832 | 1 (0.999-1) | 0.892 |
| Allopregnanediol | 37.876 ± 50.431 | 30.621 ± 31.011 | 0.538 | 0.997 (0.983-1.011) | 0.641 |
| Allopregnanolone | 6.936 ± 11.501 | 5.186 ± 6.273 | 0.499 | 0.981 (0.919-1.047) | 0.564 |
| 3α-OH-Progesterone | 1.069 ± 0.984 | 1.037 ± 0.636 | 0.891 | 0.954 (0.478-1.905) | 0.893 |
| 20α-OH-Progesterone | 3.928 ± 4.485 | 8.678 ± 7.521 | 0.013 | 1.13 (1.016-1.256) | 0.024 |
| 5α-Dihydroprogesterone | 1.347 ± 1.204 | 1.237 ± 0.809 | 0.703 | 0.923 (0.525-1.624) | 0.782 |
| Progesterone | 0.81 ± 0.728 | 1.277 ± 0.75 | 0.034 | 2.372 (1.002-5.616) | 0.049 |
*
P and OR (95% CI) were adjusted by age and BMI.